Abi Vijenthira, MD, and Anca Prica, MD, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with diffuse large B-cell lymphoma, and why the results of their study differed from a similar study published in the journal Blood in December 2022.
Catch up on earlier episodes of The HemOnc Pulse here.